Biogen Inc.
(NASDAQ : BIIB)

( )
BIIB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading BIIB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.80%69.291.0%$931.38m
AMGNAmgen Inc.
-0.09%173.140.8%$656.50m
BIIBBiogen Inc.
-0.71%286.900.9%$536.61m
CELGCelgene Corporation
-1.42%119.441.0%$479.99m
REGNRegeneron Pharmaceuticals, Inc.
0.12%371.611.9%$348.38m
ALXNAlexion Pharmaceuticals, Inc.
0.83%129.892.0%$299.57m
TSROTESARO, Inc.
-0.05%190.2715.3%$198.98m
INCYIncyte Corporation
1.55%122.362.3%$170.12m
ILMNIllumina, Inc.
-0.75%162.153.9%$148.02m
VRTXVertex Pharmaceuticals Incorporated
-2.02%86.552.6%$140.07m
CLVSClovis Oncology, Inc.
-4.27%62.9916.4%$132.37m
EXELExelixis, Inc.
-0.04%23.115.5%$131.47m
AAgilent Technologies, Inc.
-0.54%51.351.7%$117.26m
ACADACADIA Pharmaceuticals Inc.
-0.20%39.2019.0%$93.83m
BMRNBioMarin Pharmaceutical Inc.
0.41%90.244.0%$89.98m

Company Profile

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.